Antares Pharma, inc. (NYSE Amex: AIS) today announced that Paul K. Wotton, Ph.D., President and Chief Executive Officer will present at the 31st Annual Cowen Health Care Conference on Monday, March 7, 2011 at 2:30 p.m. ET (Eastern Time).

A live webcast of the presentation will be available at wsw.com/webcast/cowen3/ais/. The webcast will automatically be archived approximately three hours after the live event and will be available for 90 days.

About Antares Pharma

Antares Pharma focuses on self-injection pharmaceutical products and topical gel-based medicines. The Company’s subcutaneous and intramuscular injection technology platforms include Vibex? disposable pressure-assisted auto injectors, Valeo?/Vision? reusable needle-free injectors, and disposable multi-use pen injectors. in the injector area, Antares Pharma has a multi-product deal with Teva Pharmaceutical Industries, ltd that includes Tev-Tropin? human growth hormone and a partnership with Ferring Pharmaceuticals. in the gel-based area, the Company’s lead product candidate is Anturol?, an oxybutynin ATD? gel that has completed Phase 3 studies for the treatment of OAB (overactive bladder). Antares also has a partnership with BioSante that includes LibiGel? (transdermal testosterone gel) in Phase 3 clinical development for the treatment of female sexual dysfunction (FSD), and Elestrin? (estradiol gel) indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, and currently marketed in the U.S. Antares Pharma has corporate headquarters in Ewing, New Jersey, with subsidiaries performing research, development and product commercialization activities in Minneapolis, Minnesota and Muttenz, Switzerland.

Antares Pharma, inc.Robert F. AppleChief Financial Officer609-359-3020orInvestors:Westwicke Partners, LLCJohn Media:Tiberend Strategic Advisors, inc.Tamara